SCHEMBL23458065

SCHEMBL23458065

Cc1ccc(-n2cnc(C=O)c2C)nc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.35
CCR1 P32246 1/20 0.34
CCR5 P51681 1/20 0.34
CCR8 P51685 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
CYP2A6 P11509 1/20 0.34
RAB9A P51151 2/20 0.34
GRIN2D O15399 1/20 0.34
GRIN3B O60391 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2A Q12879 1/20 0.34
GRIN2B Q13224 1/20 0.34
GRIN2C Q14957 1/20 0.34
GRIN3A Q8TCU5 1/20 0.34
NPC1 O15118 1/20 0.34
TP53 P04637 1/20 0.34
PKM P14618 1/20 0.34
STAT3 P40763 1/20 0.34
STAT1 P42224 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9043362 0.71 ALDH1A1 (0.50) KMT2ARAB9AGRIN2DGRIN3BGRIN1
SCHEMBL23481299 0.71 CCR1 (0.34) KMT2ACCR1CCR5CCR8HDAC6
SCHEMBL30899605 0.71 KCNJ1 (0.49) KMT2ACYP2A6KCNJ1ALDH1A1
SCHEMBL23458043 0.71 ELANE (0.39) HDAC6CYP2A6KCNJ1ALDH1A1
SCHEMBL23458074 0.71 CCR1 (0.34) KMT2ACCR1CCR5CCR8HDAC6
SCHEMBL23458243 0.68 GABRG2 (0.43) RAB9ANPC1TP53SMN1; SMN2ALDH1A1
SCHEMBL23457996 0.68 GRIN2D (0.32) KMT2ACCR1CCR5CCR8HDAC6
SCHEMBL23565263 0.67 GPR119 (0.44) KMT2ACCR1CCR5CCR8HDAC6
SCHEMBL6071352 0.65
SCHEMBL1699061 0.65 ALDH1A1 (0.41) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528784-B2 Alkynyl-(heteroaryl)-carboxamide HCN1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2026-01-20 US disclosed
CN-114746408-B Alkynyl- (heteroaryl) -carboxamide HCN1 inhibitors 豪夫迈·罗氏有限公司 2025-02-14 CN disclosed
EP-4069685-A1 ALKYNYL-(HETEROARYL)-CARBOXAMIDE HCN1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2022-10-12 EP disclosed
US-20220306607-A1 ALKYNYL-(HETEROARYL)-CARBOXAMIDE HCN1 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2022-09-29 US disclosed
CN-114746408-A Alkynyl- (heteroaryl) -carboxamide HCN1 inhibitors 豪夫迈·罗氏有限公司 2022-07-12 CN disclosed
WO-2021110574-A1 ALKYNYL-(HETEROARYL)-CARBOXAMIDE HCN1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2021-06-10 WO disclosed
WO-2021110574-A1 ALKYNYL-(HETEROARYL)-CARBOXAMIDE HCN1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2021-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12528784-B2 Alkynyl-(heteroaryl)-carboxamide HCN1 inhibitors HCN1, HCN2, HCN3 KMT2A 3220/4885CCR1 59/4885CCR5 269/4885
US-20220306607-A1 ALKYNYL-(HETEROARYL)-CARBOXAMIDE HCN1 INHIBITORS HCN1, HCN2, HCN3 KMT2A 1852/4885CCR1 1044/4885CCR5 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.